Type II kinase inhibitors: an opportunity in cancer for rational design.

With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored molecules has brought a revolution in medicinal chemistry for treating tumours caused by kinase malfunctioning. Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks. Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules. Furthermore, we present the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance.

[1]  Allan Wissner,et al.  Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.

[2]  Allard Kaptein,et al.  Irreversible protein kinase inhibitors: balancing the benefits and risks. , 2012, Journal of medicinal chemistry.

[3]  T. Niwa,et al.  Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[4]  James D. Griffin,et al.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. , 2010, Blood.

[5]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[6]  A. Ardavanis,et al.  Cardiotoxicity induced by tyrosine kinase inhibitors , 2009, Acta oncologica.

[7]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[8]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[9]  J. Mestan,et al.  Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. , 2002, Journal of medicinal chemistry.

[10]  T. Clackson,et al.  Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance , 2011, Chemical biology & drug design.

[11]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[12]  Juswinder Singh,et al.  Targeted covalent drugs of the kinase family. , 2010, Current opinion in chemical biology.

[13]  A. Coxon,et al.  Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. , 2007, Bioorganic & medicinal chemistry letters.

[14]  M. Zucchetti,et al.  Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .

[15]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[16]  Richard B. Silverman,et al.  The Organic Chemistry of Drug Design and Drug Action , 1992 .

[17]  K. Gumireddy,et al.  A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Eglen,et al.  Drug discovery and the human kinome: recent trends. , 2011, Pharmacology & therapeutics.

[19]  C. Pargellis,et al.  The kinetics of binding to p38MAP kinase by analogues of BIRB 796. , 2003, Bioorganic & medicinal chemistry letters.

[20]  M. Shibuya,et al.  Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model , 2008, Cancer science.

[21]  N. Gray,et al.  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. , 2010, Bioorganic & medicinal chemistry letters.

[22]  B. Hasinoff.  The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. , 2010, Toxicology and applied pharmacology.

[23]  G. Ehninger,et al.  P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.

[24]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[25]  T. Clackson,et al.  Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[26]  Christopher Hulme,et al.  The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. , 2010, Bioorganic & medicinal chemistry.

[27]  Abran Q. Costales,et al.  Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[28]  F. Giles,et al.  Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib , 2009, Drug design, development and therapy.

[29]  C. Grütter,et al.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. , 2009, Journal of medicinal chemistry.

[30]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[31]  T. Hambley,et al.  Targeted cancer therapeutics. , 2009, Cancer research.

[32]  J. Pollard,et al.  Discovery and development of aurora kinase inhibitors as anticancer agents. , 2009, Journal of medicinal chemistry.

[33]  Wolfgang Jahnke,et al.  Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦ , 2008, Journal of Biological Chemistry.

[34]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[35]  M. Baccarani,et al.  Dual tyrosine kinase inhibitors in chronic myeloid leukemia , 2005, Leukemia.

[36]  L. Stewart,et al.  Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. , 2011, Cancer cell.

[37]  D. Moras,et al.  Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. , 2011, Journal of medicinal chemistry.

[38]  Yasunari Fujiwara,et al.  KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. , 2006, Cancer research.

[39]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[40]  W. Sippl,et al.  Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT , 2009, PloS one.

[41]  Paul Reichert,et al.  Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. , 2009, Biochemistry.

[42]  D. Ullmann,et al.  HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature. , 2011, Methods in enzymology.

[43]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[44]  Keith Abe,et al.  Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. , 2002, Journal of medicinal chemistry.

[45]  J. Mestan,et al.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL , 2006, British Journal of Cancer.

[46]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[47]  J. Mestan,et al.  Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. , 2004, Bioorganic & medicinal chemistry letters.

[48]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[49]  B. Druker,et al.  The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. , 2011, Cancer research.

[50]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[51]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[52]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[53]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[54]  H. Kantarjian,et al.  Practical advice for determining the role of BCR‐ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia , 2011, Cancer.

[55]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[56]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[57]  R. Engh,et al.  FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. , 2009, Cancer research.

[58]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[59]  Nanxin Li,et al.  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. , 2012, ACS medicinal chemistry letters.

[60]  K. Glaser,et al.  Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. , 2007, Journal of medicinal chemistry.

[61]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[62]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[63]  Ling Wang,et al.  AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. , 2006, Cancer research.

[64]  Stover,et al.  New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis , 2000, Journal of medicinal chemistry.

[65]  J. S. Johnson,et al.  Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. , 2001, Bioorganic & medicinal chemistry letters.

[66]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[67]  A. Doherty,et al.  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. , 2008, Bioorganic & medicinal chemistry letters.

[68]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[69]  Wei-Sheng Huang,et al.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.

[70]  A. Ullrich,et al.  Strategies to overcome resistance to targeted protein kinase inhibitors , 2004, Nature Reviews Drug Discovery.

[71]  S. Moro,et al.  ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents. , 2009, Anti-cancer agents in medicinal chemistry.

[72]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[73]  Taebo Sim,et al.  A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. , 2010, Journal of medicinal chemistry.

[74]  B. Druker,et al.  Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. , 2006, Blood.

[75]  K. Kolaja,et al.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.

[76]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[77]  D. Boschelli,et al.  2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. , 1998, Journal of medicinal chemistry.

[78]  M. Vieth,et al.  Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.

[79]  Xiao-Gao Liu,et al.  Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. , 2004, Bioorganic & medicinal chemistry letters.

[80]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[81]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[82]  Rongshi Li,et al.  Kinase Inhibitor Drugs , 2009 .

[83]  C. Springer,et al.  Small molecule inhibitors of BRAF in clinical trials. , 2012, Bioorganic & medicinal chemistry letters.

[84]  R. Morphy.  Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[85]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[86]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[87]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[88]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[89]  P. Savy,et al.  Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. , 2012, Journal of medicinal chemistry.

[90]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[91]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[92]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[93]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[94]  Abran Q. Costales,et al.  Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. , 2008, Journal of medicinal chemistry.

[95]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[96]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[97]  G. Daley,et al.  9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. , 2009, Journal of medicinal chemistry.

[98]  Nikolaus Stiefl,et al.  Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. , 2010, Bioorganic & medicinal chemistry.

[99]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.